KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Bought by SG Americas Securities LLC

SG Americas Securities LLC increased its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 10.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,508 shares of the specialty pharmaceutical company’s stock after purchasing an additional 1,319 shares during the quarter. SG Americas Securities LLC’s holdings in KalVista Pharmaceuticals were worth $123,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. HighVista Strategies LLC raised its holdings in KalVista Pharmaceuticals by 4.5% in the 3rd quarter. HighVista Strategies LLC now owns 33,305 shares of the specialty pharmaceutical company’s stock worth $386,000 after purchasing an additional 1,432 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of KalVista Pharmaceuticals by 8.0% during the third quarter. JPMorgan Chase & Co. now owns 22,610 shares of the specialty pharmaceutical company’s stock valued at $262,000 after acquiring an additional 1,670 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of KalVista Pharmaceuticals by 27.3% during the second quarter. The Manufacturers Life Insurance Company now owns 15,437 shares of the specialty pharmaceutical company’s stock valued at $182,000 after acquiring an additional 3,314 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,328 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the third quarter valued at approximately $126,000.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $9.27 on Wednesday. The business has a 50 day simple moving average of $8.75 and a 200-day simple moving average of $10.58. The firm has a market capitalization of $458.12 million, a PE ratio of -2.55 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.01. On average, equities research analysts expect that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Insider Buying and Selling

In other KalVista Pharmaceuticals news, insider Paul K. Audhya sold 8,077 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total transaction of $74,793.02. Following the transaction, the insider now directly owns 94,199 shares in the company, valued at $872,282.74. This represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the transaction, the chief executive officer now owns 266,598 shares in the company, valued at $2,468,697.48. This trade represents a 5.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders acquired 136,055 shares of company stock worth $1,239,146 and sold 32,291 shares worth $304,086. 10.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. JMP Securities assumed coverage on KalVista Pharmaceuticals in a report on Friday, January 31st. They set an “outperform” rating and a $19.00 target price for the company. Citizens Jmp raised KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Finally, Bank of America assumed coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target for the company. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $23.80.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).